A Novel Vaccine Using Nanoparticle Platform to Present Immunogenic M2e against Avian Influenza Infection-Reference-Cited by-同舟云学术

A Novel Vaccine Using Nanoparticle Platform to Present Immunogenic M2e against Avian Influenza Infection

Published:2011-01-12 Issue: Volume:2011 Page:1-12
ISSN:2090-1380
Container-title:Influenza Research and Treatment
language:en
Short-container-title:Influenza Research and Treatment

Author:

Babapoor Sankhiros¹,Neef Tobias²³,Mittelholzer Christian⁴⁵,Girshick Theodore⁶,Garmendia Antonio¹,Shang Hongwei⁷,Khan Mazhar I.¹,Burkhard Peter²³

Affiliation:

1. Department of Pathobiology and Veterinary Science, University of Connecticut, 61 North Eagleville Road, Storrs, CT 06268, USA

2. Department of Molecular and Cell Biology, University of Connecticut, 91 North Eagleville Road, Storrs, CT 06269, USA

3. The Institute of Materials Science, University of Connecticut, 97 North Eagleville Road, Storrs, CT 06269, USA

4. M.E. Müller Institute, University of Basel, 50/70 Klingelbergstrasse, 4056 Basel, Switzerland

5. Institute for Medical Microbiology, University of Basel, 4003 Basel, Switzerland

6. Charles River SPAFAS, Inc., 106 RT 32 North Franklin, Storrs, CT 06254, USA

7. Department of Statistics, University of Connecticut, 215 Glenbrook Road, Storrs, CT 06269, USA

Abstract

Using peptide nanoparticle technology, we have designed two novel vaccine constructs representing M2e in monomeric (Mono-M2e) and tetrameric (Tetra-M2e) forms. Groups of specific pathogen free (SPF) chickens were immunized intramuscularly with Mono-M2e or Tetra-M2e with and without an adjuvant. Two weeks after the second boost, chickens were challenged with 107.2 EID50 of H5N2 low pathogenicity avian influenza (LPAI) virus. M2e-specific antibody responses to each of the vaccine constructs were tested by ELISA. Vaccinated chickens exhibited increased M2e-specific IgG responses for each of the constructs as compared to a non-vaccinated group. However, the vaccine construct Tetra-M2e elicited a significantly higher antibody response when it was used with an adjuvant. On the other hand, virus neutralization assays indicated that immune protection is not by way of neutralizing antibodies. The level of protection was evaluated using quantitative real time PCR at 4, 6, and 8 days post-challenge with H5N2 LPAI by measuring virus shedding from trachea and cloaca. The Tetra-M2e with adjuvant offered statistically significant (P<0.05) protection against subtype H5N2 LPAI by reduction of the AI virus shedding. The results suggest that the self-assembling polypeptide nanoparticle shows promise as a potential platform for a development of a vaccine against AI.

Funder

U.S. Department of Agriculture

Publisher

Hindawi Limited

Subject

Virology,Infectious Diseases,Epidemiology

Link

http://downloads.hindawi.com/archive/2011/126794.pdf

Reference34 articles.

1. Detection of Antibodies to the Nonstructural Protein (NS1) of Avian Influenza Viruses Allows Distinction Between Vaccinated and Infected Chickens

2. The use of vaccination to combat multiple introductions of Notifiable Avian Influenza viruses of the H5 and H7 subtypes between 2000 and 2006 in Italy

3. Avian influenza vaccines and therapies for poultry